Sovilnesib

Phase 1Small molecule

VVolastra Therapeutics, Inc.

Sovilnesib is one of 50 small molecule programs targeting Ovarian Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

33 2

Hycamtin

MMeitheal

Phase 3

26 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 5

Femara

Novartis

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

23 7

Rubraca

Bristol-Myers Squibb

Phase 3

6 8

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 9

Neulasta

Amgen

Phase 3

2 10

Casodex

IIstituto Clinico Humanitas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Study of Sovilnesib in Subjects With Ovarian Cancer

Active, not recruiting·VVolastra Therapeutics, Inc.·Phase 1·NCT06084416·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sovilnesib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sovilnesib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sovilnesib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Volastra Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVolastra Therapeutics, Inc.

Sovilnesib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News